You should consider shares of Pinduoduo Inc. (NASDAQ:PDD) and Titan Pharmaceuticals Inc. (NASDAQ:TTNP) if you are looking for a great stocks to invest in. Starting with the PDD shares, which traded at $36.51 at the close of the recent session, gaining 2.01%. On Tuesday, the company’s shares shed $0.72 from its value which represented in intraday trading. The stock is now -3.46% lower in year-to-date (YTD) trading. PDD’s intraday high was $37.29 while its lowest price touched $36.26. The stock’s 52-week high price is $45.25, which means the current price is at -19.31%. In terms of trading activity, the daily trading volume fell to 6504281 against 200-day average trading volume of 6,836,581 shares.
What are analyst forecasts for Pinduoduo Inc. (NASDAQ:PDD)?
At a consensus rating of 4.40, PDD is trending as a streaking Moderate Buy, as it has been the case a month ago when 10 analysts called it a Moderate Buy. Two months ago, 10 analysts recommended, on average, that PDD stock is a Moderate Buy. The Services company’s shares’ overall bullish trend saw it close lower on Tuesday compared to its opening price of $36.43 on the day.
Forecasts for Pinduoduo Inc. (NASDAQ:PDD) give the stock a fair value for the growth of 87.3% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $287.55, which means the price per share could rise by nearly $251.04. The price range target is between a low of $145.55 and a high of $425.25. The stock would need to gain by about $91.41 to hit the estimated high or 0.51% from its 12-month low.
The consensus among 27 analysts is that it is a good time for one to Overweight in the Pinduoduo Inc. 21 analysts rate PDD as a Buy, with 3 of 27 analysts rate it as a Sell. 0 have valued the stock as Overweight and 3 have recommended that investors Hold.
Pinduoduo Inc. (NASDAQ:PDD) Upgrades and Downgrades
In terms of rating changes, Credit Suisse on February 04, 2020, Downgrade Pinduoduo Inc. (PDD) at Neutral. They believe the stock could reach $40.80 in the near term. Analysts at Credit Suisse have assigned a Outperform rating for the stock in their research note on January 06, 2020 with an estimated price target of $47.50. Moreover, Macquarie analysts issued a rating of Outperform for the stock on November 22, 2019. On October 09, 2019, the stock earned a Neutral rating due to an analyst call from Nomura, while analysts from CLSA on September 06, 2019 suggested that the stock is Buy.
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) adds -$0.01 on Tuesday
The TTNP stock has risen 20.50% year-to-date and is currently trading at $0.23, which is -90.45% below its 52-week high. The company shares lost -2.13% on the day and have risen nearly 64.72% off a low hit. At current levels, Titan Pharmaceuticals Inc. has a valuation of about $3.60M. As of 02/04/20, this stock has fallen -19.81% during the week and closed at $0.24 in the previous session. However, recent Titan Pharmaceuticals Inc. stock performance shows that TTNP shares are -10.14% down over the last month, and 32.37% up for the last three months.
Earnings per share (EPS) estimates for the current quarter are -$0.31, with the trailing 12-month share earnings at -$1.53. The ratio is expected to be up by 63.00% for the current year 2019 and 77.50% for next year. But will the TTNP stock surprise in the current quarter results, where the -$0.18 actual EPS reported on 9/29/2019 surprised by 14.30% or was higher by $0.03 from the estimated -$0.21.
Sales Growth to climb 69.90% for the year
How well will Titan Pharmaceuticals Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $450k and $1.4M in current quarter sales. The consensus estimated for the current quarter is $920k from sales. Forecasts for this fiscal year are between $2.84M and $3.8M and the consensus estimate for sales is at $3.32M. TTNP has its next quarter sales estimates at between $820k and $820k, with the quarter-over-quarter growth estimates at -25.50% and the annual growth forecast for the year at 69.90%.
Who owns shares in Titan Pharmaceuticals Inc. (TTNP)?
Let’s briefly focus on the share ownership of the Titan Pharmaceuticals Inc. (NASDAQ:TTNP) stock, where we find that 11.10% of shares are held by institutions.